title: [Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
abstract: OBJECTIVE
  To observe the preliminary efficacies and adverse events of sunitinib in the treatment of metastatic breast cancer ulcer.
  
  
  METHODS
  From December 2008 to May 2010, patients with advanced breast cancer ulcer took a single sunitinib. The dosage was adjusted on the basis of adverse events. And clinical response was evaluated.
  
  
  RESULTS
  Nine patients with advanced breast cancer ulcer finished the treatment. The objective response and the clinical benefit time to progression of sunitinib were 3 and 7 patients with metastatic breast cancer ulcer, and the median time to progression (TTP) was 2.0 months. The most common adverse events included fatigue, hand-foot syndrome, neutropenia, thrombocytopenia and hypertension.
  
  
  CONCLUSIONS
  Single-agent sunitinib treatment of refractory advanced breast cancer ulcer has marked efficacies. However, neutropenia, thrombocytopenia and hypertension are the major dose-limited toxicities.
authors: Breast Cancer Department, 307 Hospital of PLA, Beijing 100071, China.
authors: Xin
authors: X
authors: Zhao
authors: Xiang-ying
authors: XY
authors: Meng
authors: Bing
authors: B
authors: Sun
authors: Li-juan
authors: LJ
authors: Ding
authors: Ze-fei
authors: ZF
authors: Jiang
authors: San-tai
authors: ST
authors: Song
authors: Shi-kai
authors: SK
authors: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome; D014456:Ulcer / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib